Issued U.S. patent strengthens IP for Allon technology platform

16-Apr-2009 - USA

Allon Therapeutics Inc. announced that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a U.S. patent covering the chemical composition of two component peptides and covering their use in drugs to protect brain cells from degenerative diseases.

Gordon McCauley, President and CEO of Allon, said the new peptides have demonstrated neuroprotection characteristics in preclinical studies by protecting against neuronal cell death after exposure to the potent neurotoxin tetrodotoxin.

“These new peptides are additional pipeline candidates from our proprietary ADNF technology platform and distinct from our lead ADNF product candidate AL-309” said McCauley. “We are encouraged that the capacity of our platform technologies to generate multiple product candidates has again been validated by the issuance of these patents.”

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances